Articles published by Gilead Sciences, Inc.

...

U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome

January 31, 2022

From Gilead Sciences, Inc.

Via Business Wire

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

January 21, 2022

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

January 18, 2022

From Gilead Sciences, Inc.

Via Business Wire

Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer

January 10, 2022

From Gilead Sciences, Inc.

Via Business Wire

Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19

December 22, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns

December 21, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conference

December 21, 2021

From Gilead Sciences, Inc.

Via Business Wire

European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression

December 21, 2021

From Gilead Sciences, Inc.

Via Business Wire

Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan

December 16, 2021

From Gilead Sciences, Inc.

Via Business Wire

Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma

December 13, 2021

From Gilead Sciences, Inc.

Via Business Wire

Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma

December 11, 2021

From Gilead Sciences, Inc.

Via Business Wire

Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma

December 11, 2021

From Gilead Sciences, Inc.

Via Business Wire

Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

December 11, 2021

From Gilead Sciences, Inc.

Via Business Wire

Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study

December 10, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

November 29, 2021

From Gilead Sciences, Inc.

Via Business Wire

Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

November 23, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta

November 19, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences to Present at Upcoming Investor Conference

November 18, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

November 18, 2021

From Gilead Sciences, Inc.

Via Business Wire

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint

November 10, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®

November 09, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline

November 04, 2021

From Gilead Sciences, Inc.

Via Business Wire

Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting

October 29, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer

October 28, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Announces Third Quarter 2021 Financial Results

October 28, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

October 26, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV

October 21, 2021

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia

October 19, 2021

From Gilead Sciences, Inc.

Via Business Wire

U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations

October 18, 2021

From Gilead Sciences, Inc.

Via Business Wire

Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer

October 15, 2021

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Articles published by Gilead Sciences, Inc.

Starting at /week.